These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17380730)

  • 21. Propionibacterium acnes resistance to antibiotics in acne patients.
    Leyden JJ; McGinley KJ; Cavalieri S; Webster GF; Mills OH; Kligman AM
    J Am Acad Dermatol; 1983 Jan; 8(1):41-5. PubMed ID: 6219134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of topical benzoyl peroxide/clindamycin versus topical clindamycin and vehicle in the reduction of Propionibacterium acnes.
    Leyden JJ
    Cutis; 2002 Jun; 69(6):475-80. PubMed ID: 12078851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Topical taurine bromamine, a new candidate in the treatment of moderate inflammatory acne vulgaris: a pilot study.
    Marcinkiewicz J; Wojas-Pelc A; Walczewska M; Lipko-Godlewska S; Jachowicz R; Maciejewska A; Białecka A; Kasprowicz A
    Eur J Dermatol; 2008; 18(4):433-9. PubMed ID: 18573718
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro resistance of Propionibacterium acnes and Staphylococcus epidermidis to antibiotics: should our antibiotic prescription practices for the treatment of acne be changed?].
    Bourgault-Villada I
    Ann Dermatol Venereol; 1998 Dec; 125(12):879-80. PubMed ID: 9922858
    [No Abstract]   [Full Text] [Related]  

  • 25. Clindamycin/benzoyl peroxide gel: a review of its use in the management of acne.
    Warner GT; Plosker GL
    Am J Clin Dermatol; 2002; 3(5):349-60. PubMed ID: 12069641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treating acne: avoid the development of antibiotic resistance by applying topical and combined therapy].
    Abeck D
    MMW Fortschr Med; 2003 Dec; 145(51-52):29. PubMed ID: 14974325
    [No Abstract]   [Full Text] [Related]  

  • 27. [General antibiotic therapy in acne].
    Dréno B
    Rev Prat; 2002 Apr; 52(8):841-3. PubMed ID: 12053791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bacterial resistance in acne? A meta-analysis of the controversy].
    Alvarez-Sánchez M; Rodríguez-Ayala E; Ponce-Olivera RM; Tirado-Sánchez A; Arellano-Mendoza MI
    Cir Cir; 2016; 84(3):190-5. PubMed ID: 26738649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current issues in antimicrobial therapy for the treatment of acne.
    Leyden JJ
    J Eur Acad Dermatol Venereol; 2001; 15 Suppl 3():51-5. PubMed ID: 11843235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of oral antibiotics in treating acne vulgaris: a new approach.
    Farrah G; Tan E
    Dermatol Ther; 2016 Sep; 29(5):377-384. PubMed ID: 27306750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Topical antibiotics in acne?].
    van der Meeren HL; van Everdingen JJ; Rampen FH
    Ned Tijdschr Geneeskd; 1984 Jul; 128(27):1281-4. PubMed ID: 6235455
    [No Abstract]   [Full Text] [Related]  

  • 32. Current concepts of the pathogenesis of acne: implications for drug treatment.
    Gollnick H
    Drugs; 2003; 63(15):1579-96. PubMed ID: 12887264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical nadifloxacin 1% cream vs. topical erythromycin 4% gel in the treatment of mild to moderate acne.
    Tunca M; Akar A; Ozmen I; Erbil H
    Int J Dermatol; 2010 Dec; 49(12):1440-4. PubMed ID: 21091683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Fundamental studies on antibacterial activity of clindamycin against Propionibacterium acnes].
    Komagata Y; Komiyama K; Nomura S
    Jpn J Antibiot; 1998 Feb; 51(2):130-6. PubMed ID: 9575439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of subminimal inhibitory concentrations of erythromycin, tetracycline, clindamycin, and minocycline on the neutrophil chemotactic factor production in Propionibacterium acnes biotypes 1-5.
    Akamatsu H; Nishijima S; Takahashi M; Ushijima T; Asada Y
    J Dermatol; 1991 May; 18(5):247-51. PubMed ID: 1834712
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The antimicrobial effect of CEN1HC-Br against Propionibacterium acnes and its therapeutic and anti-inflammatory effects on acne vulgaris.
    Han R; Blencke HM; Cheng H; Li C
    Peptides; 2018 Jan; 99():36-43. PubMed ID: 29108811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Taurine bromamine: a new therapeutic option in inflammatory skin diseases.
    Marcinkiewicz J
    Pol Arch Med Wewn; 2009 Oct; 119(10):673-6. PubMed ID: 19847145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of irritative potential of nadifloxacin 1% when combined with other topical anti-acne agents.
    Wilhelm KP; Wilhelm D; Neumeister C; Zsolt I; Schwantes U
    Clin Exp Dermatol; 2012 Mar; 37(2):112-7. PubMed ID: 22103435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term administration of oral macrolides for acne treatment increases macrolide-resistant Propionibacterium acnes.
    Nakase K; Okamoto Y; Aoki S; Noguchi N
    J Dermatol; 2018 Mar; 45(3):340-343. PubMed ID: 29235673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Rationally Designed Multifunctional Antibiotic for the Treatment of Drug-Resistant Acne.
    Ghosh S; Sinha M; Bhattacharyya A; Sadhasivam S; Megha J; Reddy S; Saini S; Singh H; Kumar D; Kaur SP; Mishra M; Usharani D; Ghosh S; Sengupta S
    J Invest Dermatol; 2018 Jun; 138(6):1400-1408. PubMed ID: 29409921
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.